EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • February 25th, 2011 • Geron Corp • Pharmaceutical preparations • New York
THIS EXCLUSIVE LICENSE AGREEMENT (the “Agreement”) is made and entered into as of December 6, 2010 (the “Effective Date”) by and between GERON CORPORATION, a corporation organized and existing under the laws of Delaware and having its principal place of business at 230 Constitution Drive, Menlo Park, CA 94026 (“Geron”) and ANGIOCHEM, INC., a corporation organized and existing under the laws of Canada and having its principal place of business at 201, President-Kennedy Ave., Suite PK-R220, Montreal, Quebec, H2X 3Y7 Canada (“AngioChem”). Geron and AngioChem are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
TRANSITION AND SEPARATION AGREEMENTTransition and Separation Agreement • February 25th, 2011 • Geron Corp • Pharmaceutical preparations • California
This Transition and Separation Agreement (the “Agreement”) is made effective as of the eighth (8th) day following the date Executive signs this Agreement (the “Effective Date”) by and between Thomas Okarma (“Executive”) and Geron Corporation (the “Company”), with reference to the following facts:
